Vetr Upgrades Merrimack Following Earnings, Licensing Rumors
November 29, 2016 at 14:52 PM EST
The Vetr crowd upgraded their rating for Merrimack Pharmaceuticals Inc (NASDAQ: MACK) from the previous rating of 2 stars (Sell), ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.